Total Funding
65
30
Total FundingPost-IPO Debt raised
Growth Score
-3 pts
Heat Score
-12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
149546
Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.
Gavin Wood: Chief Financial Officer- William (Bill) Bertrand: Chief Operating Officer
About the Company
Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroys cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses.
The company was incorporated in 2007 and is based in Abingdon,
United Kingdom.
